Working Group Member
Neurologist and Associate Professor, Department of Neurology, Clinical Neurological Sciences, London Health Sciences Centre, Western University
NMD4C Working Group(s): Clinical Curriculum Development
Dr. Shoesmith earned her Bachelor of Science degree from the University of Winnipeg in 1996 and her MD from the University of Manitoba in 2000. She completed her neurology residency at Western University in 2005. From 2005 to 2007, Dr. Shoesmith completed a neuromuscular clinical fellowship with a specific focus on treatment and care of ALS patients at Western University. In 2007, Dr. Shoesmith joined the neurology faculty at the London Health Sciences Centre as a neuromuscular neurologist. She also has a general neuromuscular clinic and an EMG clinic. In 2010, Dr. Shoesmith became the Motor Neuron Diseases Clinic Director at LHSC. She is the site principal investigator for all ALS clinical trials run at LHSC.
Dr. Shoesmith is actively involved in teaching of residents and medical students. She is the neuromuscular education coordinator for residents and fellows. She is also a co-director of the neurosciences curriculum for medical students at the Schulich School of Medicine & Dentistry.
Within the NMD4C, Dr. Shoesmith is a part of the Curriculum Development working group.
Wilson, KM, Katona, E, Glaria, I, Carcolé, M, Swift, IJ, Sogorb-Esteve, A et al.. Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2022. PMID:35379698
Foster, PH, Russell, LL, Peakman, G, Convery, RS, Bouzigues, A, Greaves, CV et al.. Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex. 2022.150 12-28 PMID:35325762
Ozzoude, M, Varriano, B, Beaton, D, Ramirez, J, Holmes, MF, Scott, CJM et al.. Investigating the contribution of white matter hyperintensities and cortical thickness to empathy in neurodegenerative and cerebrovascular diseases. Geroscience. 2022. PMID:35294697
McMillan, CT, Wuu, J, Rascovsky, K, Cosentino, S, Grossman, M, Elman, L et al.. Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approaches. Amyotroph Lateral Scler Frontotemporal Degener. 2022. 1-10 PMID:35253557
Dilliott, AA, Abdelhady, A, Sunderland, KM, Farhan, SMK, Abrahao, A, Binns, MA et al.. Contribution of rare variant associations to neurodegenerative disease presentation. NPJ Genom Med. 2021.6 (1)80 PMID:34584092
Salmon, K, Anoja, N, Breiner, A, Chum, M, Dionne, A, Dupré, N et al.. Genetic testing for amyotrophic lateral sclerosis in Canada - an assessment of current practices. Amyotroph Lateral Scler Frontotemporal Degener. 2022.23 (3-4)305-312 PMID:34569363
Oliveira, LM, Rastin, T, Nimmo, GAM, Ross, JP, Dion, PA, Zhang, M et al.. Occurrence of Amyotrophic Lateral Sclerosis in Type 1 Gaucher Disease. Neurol Genet. 2021.7 (4)e600 PMID:34017912
Slayter, J, Hodgkinson, V, Lounsberry, J, Brais, B, Chapman, K, Genge, A et al.. A Canadian Adult Spinal Muscular Atrophy Outcome Measures Toolkit: Results of a National Consensus using a Modified Delphi Method. J Neuromuscul Dis. 2021.8 (4)579-588 PMID:33867362
Shoesmith, C, Abrahao, A, Benstead, T, Chum, M, Dupre, N, Izenberg, A et al.. Canadian best practice recommendations for the management of amyotrophic lateral sclerosis. CMAJ. 2020.192 (46)E1453-E1468 PMID:33199452
Shefner, JM, Andrews, JA, Genge, A, Jackson, C, Lechtzin, N, Miller, TM et al.. A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2021.22 (3-4)287-299 PMID:32969758See more on PubMed